Abstract:Exquisite binding specificity is essential for many protein functions but is difficult to engineer. Many biotechnological or biomedical applications require the discrimination of very similar ligands, which poses the challenge of designing protein sequences with highly specific binding profiles. Experimental methods for generating specific binders rely on in vitro selection, which is limited in terms of library size and control over specificity profiles. Additional control was recently demonstrated through high-throughput sequencing and downstream computational analysis. Here we follow such an approach to demonstrate the design of specific antibodies beyond those probed experimentally. We do so in a context where very similar epitopes need to be discriminated, and where these epitopes cannot be experimentally dissociated from other epitopes present in the selection. Our approach involves the identification of different binding modes, each associated with a particular ligand against which the antibodies are either selected or not. Using data from phage display experiments, we show that the model successfully disentangles these modes, even when they are associated with chemically very similar ligands. Additionally, we demonstrate and validate experimentally the computational design of antibodies with customized specificity profiles, either with specific high affinity for a particular target ligand, or with cross-specificity for multiple target ligands. Overall, our results showcase the potential of leveraging a biophysical model learned from selections against multiple ligands to design proteins with tailored specificity, with applications to protein engineering extending beyond the design of antibodies. A great challenge in protein science is to relate sequences to physical properties, both to predict physical properties from sequences, and to design sequences with desired phenotypes. A promising solution lies in integrating large-scale selection experiments, high-throughput sequencing, and machine learning techniques. However, existing models often focus solely on the property under selection ("fitness"), lacking interpretability. This limits our fundamental understanding of proteins and our ability to engineer them for desired properties, especially those not directly selectable in experiments. Previous studies have shown that incorporating biophysical constraints into models can offer quantitative insights, particularly in transcription factors Here, we demonstrate that when coupled with extensive experiments, such modeling can not only predict physical features but also design new proteins with specific properties. Our demonstration involves a problem of primary biotechnological and biomedical interest: the design of antibodies with defined specificity profiles. We focus on one of the most challenging tasks in the field, designing antibodies capable of discriminating between structurally and chemically similar ligands. This approach has applications for creating antibodies with both specific and cross-specific binding properties and for mitigating experimental artifacts and biases in selection experiments. The combination of biophysics-informed modeling and extensive selection experiments holds broad applicability beyond antibodies, offering a powerful toolset for designing proteins with desired physical properties.

Structure‐based computational design of antibody mimetics: challenges and perspectives

Leveraging Artificial Intelligence to Expedite Antibody Design and Enhance Antibody–Antigen Interactions

AI driven B-cell Immunotherapy Design

In Silico Approaches to Deliver Better Antibodies by Design: The Past, the Present and the Future

Antibodies: Computer-Aided Prediction of Structure and Design of Function

Computational design of developable therapeutic antibodies: efficient traversal of binder landscapes and rescue of escape mutations

Machine-designed biotherapeutics: opportunities, feasibility and advantages of deep learning in computational antibody discovery

Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen

IsAb: a computational protocol for antibody design

Prospects for the computational humanization of antibodies and nanobodies

Integrating Computational Design and Experimental Approaches for Next-Generation Biologics

AI-based IsAb2.0 for antibody design

Accelerating antibody discovery and design with artificial intelligence: recent advances and prospects

Protein design: from computer models to artificial intelligence

Nanobody engineering: computational modelling and design for biomedical and therapeutic applications

Advancing Antibody Engineering through Synthetic Evolution and Machine Learning

New Horizons in Therapeutic Antibody Discovery: Opportunities and Challenges versus Small-Molecule Therapeutics

Applying artificial intelligence to accelerate and de-risk antibody discovery

Antibody optimization enabled by artificial intelligence predictions of binding affinity and naturalness

Inference and design of antibody specificity: From experiments to models and back

A new era of antibody discovery: an in-depth review of AI-driven approaches